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OBJECTIVES The goal of this study was to determine if brain natriuretic peptide (BNP) levels are associated
with exercise capacity in patients with chronic heart failure (HF).
BACKGROUND Plasma levels of BNP are increased subject to the degree of systolic and diastolic left
ventricular dysfunction in patients with chronic HF. Exercise testing is useful to assess
functional capacity and prognosis in chronic HF.
METHODS We prospectively studied 70 consecutive patients with chronic HF (60.3  10.4 years, 51
men) referred for cardiopulmonary exercise testing. Resting BNP was obtained after 10 min
of supine rest before symptom-limited bicycle exercise testing.
RESULTS In patients with chronic HF, BNP levels correlated with oxygen uptake (VO2), both at
anaerobic threshold (VO2AT: r  0.54, p  0.001) and peak exercise (peak VO2: r 
0.56, p  0.001). Impairment of ventilatory efficiency (EqCO2: r  0.43, p  0.001) and
maximum exercise level (W % predicted: r0.44, p 0.05) correlated less well with BNP.
There was a significant inverse correlation between left ventricular ejection fraction and BNP
(r0.50, p 0.05). Brain natriuretic peptide discriminated well chronic HF patients with
a peak VO2 10 ml/min/kg (area under the receiver operating characteristic [ROC] 0.93) or
14 ml/min/kg (area under the ROC 0.72). A BNP 316 pg/ml was associated with a risk
ratio of 6.8 (95% confidence interval, 2.3 to 19.8) for a reduced exercise capacity with a peak
VO2 14 ml/min/kg.
CONCLUSIONS Brain natriuretic peptide is clearly associated with exercise capacity in chronic HF. Brain
natriuretic peptide levels show a significant correlation with the impairment of VO2 at peak
exercise and anaerobic threshold. Brain natriuretic peptide is able to differentiate between
chronic HF patients with moderately and severely impaired exercise capacity. (J Am Coll
Cardiol 2002;40:718–22) © 2002 by the American College of Cardiology Foundation
Functional disability is one of the most common problems
experienced by patients with chronic heart failure (HF).
Therefore, one of the major goals of chronic HF manage-
ment is to improve functional capacity. To accomplish this,
reliable methods for detecting and monitoring the func-
tional capacity of this population are warranted.
Some clinicians use the clinical history to monitor the
functional capacity of their patients. However, exertional
symptoms frequently underestimate the severity of func-
tional disability (1). Therefore, others prefer exercise testing
to assess functional capacity in chronic HF. Previous studies
have shown that peak exercise oxygen uptake (VO2) corre-
lates with survival in chronic HF (2,3). Improvement in
peak exercise VO2 over time is also accompanied by stable
clinical status and fewer hospitalizations (4).
Recently, brain natriuretic peptide (BNP)-guided therapy
for chronic HF has been suggested. Troughton et al. (5)
demonstrated that pharmacotherapy guided by BNP levels
reduces cardiovascular events and delays time to first car-
diovascular event compared with intensive clinically guided
therapy. Plasma concentrations of BNP are increased in
patients with chronic HF and accurately predict left ven-
tricular ejection fraction (LVEF) as well as morbidity and
mortality in these patients (6–13).
The aim of this study was to further clarify the relation
between BNP levels measured by a rapid bedside test and
functional capacity as measured by cardiopulmonary exercise
testing in patients with chronic HF.
METHODS
Patients. Seventy patients referred for the evaluation of
chronic HF or consideration of heart transplantation were
included in the analysis. All patients were in a clinically
stable condition for at least six weeks and showed no signs
of acute cardiac decompensation. All patients were on
optimized medical chronic HF therapy including
angiotensin-converting enzyme inhibitors and beta-
blockers, which was unchanged for at least six weeks.
Chronic HF was confirmed by left ventricular dysfunction
(LVEF 35%) and impairment of exercise capacity (max-
imal VO2  25 ml/min/kg). All patients had exertional
dyspnea, fatigue, or both and were classified according to
New York Heart Association functional class II to III. The
etiology of HF was defined by cardiac catheterization in all
From the *Medical Clinic I and the †Institute of Clinical Chemistry and
Pathobiochemistry, University Hospital, University of Technology, Aachen, Ger-
many. Guest Editor: Gottlieb Friesinger, II, MD.
Manuscript received March 21, 2002; revised manuscript received April 29, 2002,
accepted May 23, 2002.
Journal of the American College of Cardiology Vol. 40, No. 4, 2002
© 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(02)02032-6
patients. Left ventricular ejection fraction was evaluated
with biplane transthoracic echocardiography by the modi-
fied Simpson rule using second harmonic imaging (14).
Patients with renal failure (defined as a creatinine value
2.0 mg/dl) were excluded from the study.
Exercise test. A standard bicycle exercise protocol was used
in the postabsorptive state. Exercise began with 10 W after
a 2-min unload phase, followed by a ramp protocol with
increments of 10 W/min. Oxygen uptake, CO2 production,
and minute ventilation were measured using a breath-by-
breath gas analysis (Ja¨ger Oxycon Alpha, Wu¨rzburg, Ger-
many). A 12-lead electrocardiogram was continuously reg-
istered to exclude significant myocardial ischemia. Blood
pressure was recorded every minute by a cuff sphygmoma-
nometer. Peak VO2 was determined as the highest value in
the terminal phase of exercise; the O2 uptake at the
anaerobic threshold (VO2-AT) was determined by the
V-slope method according to Beaver. Ventilatory efficiency
(EqCO2) on exercise was defined as the slope of the VE
versus VCO2 relation. Exclusion criteria were exercise-
limiting diseases like peripheral vascular disease or degen-
erative joint disease, relevant primary pulmonary disease,
and exercise tests that were not limited by dyspnea or
fatigue. All patients reached the AT and a respiratory ratio
1.05. The physician that performed and analyzed the
cardiopulmonary exercise test was unaware of the results of
BNP testing.
Measurement of BNP plasma levels. In all patients blood
was sampled from an antecubital vein after 10 min of supine
rest before symptom-limited bicycle exercise. We used a
rapid bedside test for determination of BNP (Triage BNP,
Biosite Diagnostics, San Diego, California). The Triage
BNP test is an immunofluorometric assay for quantitative
determination of BNP in ethylenediaminetetraacetic acid-
anticoagulated whole blood or plasma (9). The peripheral
venous blood was collected into a sampling tube containing
EDTA as the anticoagulant. Within 20 min after venipunc-
ture, BNP concentrations were determined by the Triage
system by analysts that were blinded to results of ergospi-
rometry and the clinical status of the patients.
Statistics. Values are presented as mean values  SD. All
variables were tested for normal distribution by the
Kolmogorov-Smirnov test. All data was found normally
distributed. Correlations were performed using Pearson’s
correlation. Results are presented as coefficient of correla-
tion (r). The area under the receiver operating characteristic
curve (AUROC) was utilized for discrimination. The AU-
ROC provides a measure of overall accuracy that is inde-
pendent of the decision criterion. The criterion value
corresponding with the highest accuracy is the value with
the minimum false negative and false positive results at the
same time. Univariate logistic regression was performed
with the BNP criterion value as the explanatory variable and
peak VO2 14 or 10 ml/min/kg as the response variable.
All statistical tests were two-tailed, and a p value0.05 was
considered statistically significant. Data were analyzed using
SPSS 10.0 (SPSS Inc., Chicago, Illinois). The AUROC
analysis was performed with MedCalc 6.12 (MedCalc
software, Mariakerke, Belgium).
RESULTS
Patients. Overall, 70 patients with chronic HF (Table 1)
were included in this study.
BNP levels and exercise parameters. Table 2 shows the
correlation between BNP and exercise variables as well as
LVEF. Brain natriuretic peptide levels correlated best with
peak VO2 (Fig. 1a), VO2-AT and LVEF (Fig. 1b). Com-
pared with BNP levels, LVEF correlated less with peak
VO2 (r 0.43) and VO2-AT (r 0.29). The correlation of
Abbreviations and Acronyms
AT  anaerobic threshold
AUROC  area under the receiver operating
characteristic curve
BNP  brain natriuretic peptide
CI  confidence interval
EqCO2  ventilatory efficiency
HF  heart failure
LVEF  left ventricular ejection fraction
VO2  oxygen uptake
Table 1. General Patient Characteristics in 70 Patients With
Chronic Heart Failure
Characteristics Patient Values
Age (yrs) 60.3  10.4
Men 51 (73%)
Weight (kg) 75  14
Height (cm) 172  7
NYHA functional class I/II/III 2 (3%)/44 (63%)/24 (34%)
LVEF (%) 26.4  6.0
Chronic HF etiology
Idiopathic dilated CMP 41 (58.6%)
Coronary artery disease 28 (40%)
Valvular heart disease 1 (1.4%)
Medication
ACE inhibitors 57 (81%)
Diuretics 60 (86%)
Digitalis 55 (79%)
Beta-blockers 57 (81%)
Values are mean  SD or number of patients (%).
ACE  angiotensin-converting enzyme; CMP  cardiomyopathy; HF  heart
failure; LVEF  left ventricular ejection fraction; NYHA  New York Heart
Association.
Table 2. Correlation Coefficients Between BNP Levels,
Cardiopulmonary Exercise Variables and LVEF
Peak VO2 VO2-AT EqCO2 W LVEF
BNP
Correlation
coefficient
0.56 0.54 0.43 0.44 0.50
p value 0.001 0.001 0.001 0.05 0.05
BNP  brain natriuretic peptide; EqCO2  ventilatory efficiency; LVEF  left
ventricular ejection fraction; VO2 oxygen uptake; VO2-AT oxygen uptake at the
anaerobic threshold; W  maximum exercise level in watts % predicted.
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BNP with peak VO2 was better in patients with dilated
cardiomyopathy (r  0.64) compared with those with
ischemic cardiomyopathy (r  0.41). The correlation of
BNP with VO2-AT was equally good for both etiologies of
chronic HF (r  0.53 vs. 0.57).
Receiver operating characteristic curves illustrate the
sensitivity and specificity of BNP in discriminating patients
to reach a peak VO210 or14 ml/min/kg. The AUROC
was 0.93 (95% confidence interval [CI]: 0.85 to 1.0) for
peak VO2 10 ml/min/kg (Fig. 2a), indicating very good
discriminatory power. For peak VO2 14 ml/min/kg (Fig.
2b), the area under the curve was 0.72 (95% CI: 0.61 to
0.85), still demonstrating fair to good discriminatory power.
The criterion value for BNP to predict a peak VO2 10
ml/min/kg was 532 pg/ml with a sensitivity of 100% and a
specificity of 78%. A peak VO2 14 ml/min/kg was
predicted with a BNP criterion value of 316 pg/ml with a
sensitivity of 76% and a specificity of 68%. Patients with
chronic HF with BNP levels 316 pg/ml had a 6.8-fold
higher risk (95% CI: 2.3 to 19.8) to reach a peak VO2 14
ml/min/kg compared with patients with BNP levels below
this cutoff value.
DISCUSSION
Role of BNP in chronic HF. Brain natriuretic peptide is
secreted predominantly from cardiac ventricles and is af-
fected by the degree of myocardial stretch, damage, and
ischemia in the ventricle (10). Brain natriuretic peptide
levels are raised in patients with chronic HF and reflect
severity of left ventricular and right ventricular dysfunction
(11–13).
Beyond these evidences the present study demonstrated a
reliable correlation of BNP levels with exercise parameters
Figure 1. Scatter plots of brain natriuretic peptide (BNP) concentrations
versus peak oxygen uptake (VO2) (a) and left ventricular ejection fraction
(LVEF) (b).
Figure 2. Receiver operating characteristic curve of brain natriuretic
peptide for the determination of peak oxygen uptake (VO2) 10 ml/
min/kg (a) and peak VO2 14 ml/min/kg (b). AUROC  area under the
receiver operating characteristic curve.
720 Kru¨ger et al. JACC Vol. 40, No. 4, 2002
BNP and Exercise Capacity in HF August 21, 2002:718–22
such as peak VO2, VO2 at the AT, EqCO2, and with LVEF
in chronic HF. To the best of our knowledge, this is the first
study that systematically examines the correlation of a rapid
bedside BNP test with cardiopulmonary exercise testing in
patients with mild to severe symptoms of chronic HF.
Brain natriuretic peptide is more useful than atrial nati-
uretic peptide, endothelin, or norepinephrine as an inde-
pendent predictor of morbidity and mortality in patients
with chronic HF and is independent of other clinical,
hemodynamic, and neurohumoral risk factors in chronic HF
(6). Endothelin and norepinephrine are closely correlated
with exercise capacity in patients with chronic HF (15,16).
However, the use of these markers, which give prognostic
information in chronic HF, such as norepinephrine, renin,
and endothelin, is difficult, impractical, and associated with
long-lasting assays (17). For this reason BNP seems to be
the most simple, reliable, readily available, and promising
laboratory marker of cardiac dysfunction at present.
Importance of point-of-care testing of BNP in chronic
HF. A rapid bedside BNP test has several advantages
compared with the formerly used assay systems to determine
BNP (9). The major advantage is its rapid and accurate
measurement of BNP from whole blood with 24-h avail-
ability in a routine laboratory or at the point-of-care.
Additional time-consuming preparation, centrifugation, ex-
traction, and incubation steps can be omitted. Thus, a fast
BNP determination is possible, which makes the recently
introduced BNP-guided therapy for chronic HF more
feasible, especially in an ambulatory setting.
Cardiopulmonary exercise testing as a gold standard is
costly, time consuming and has limited availability, so that,
with respect to the good correlation of BNP with exercise
variables, BNP may be a cost-effective, generally available
and reliable tool for the guidance of chronic HF therapy.
Role of exercise testing in chronic HF. Exercise testing
with gas-exchange analysis has become a routine clinical
tool for the evaluation of patients with chronic HF and is
predictive of mortality (2,18–22). Therefore, current guide-
lines recommend exercise testing to select appropriate can-
didates for heart transplantation (23). Peak VO2 is less
valuable in patients with mild symptoms of CHF, although
their annual mortality is still high with rates of 8% to 10%
(24). In this subset of patients, enhanced ventilatory re-
sponse to exercise (EqCO2) predicts poor prognosis,
whereas peak VO2 is not associated with outcome (25). A
significant number of patients with severe chronic HF do
not reach maximal exertion. Therefore, some authors as-
sessed the prognostic significance of respiratory data during
submaximal exercise. Pardaens et al. (20) found that respi-
ratory data during submaximal exercise are significant pre-
dictors of outcome in chronic HF, but inferior to that of
peak VO2. Thus, this study examined not only oxygen
kinetics at exercise, but also EqCO2.
Many authors concluded that peak VO2 provides superior
prognostic information in chronic HF (20). Various cutoff
values have been proposed for decision making. Mancini et
al. (2) observed that cardiac transplantation could be safely
deferred in ambulatory patients with left ventricular dys-
function and peak exercise VO2 of 14 ml/min/kg. The
highest mortality rate is seen in patients with chronic HF
with a peak VO2 of 10 ml/min/kg (21,22). In our study a
criterion value for BNP of 532 pg/ml exhibits a very good
discriminative power for the prediction of a severely reduced
peak VO2 of 10 ml/min/kg, and a criterion value of 316
pg/ml also has good discriminatory power for the prediction
of a peak VO2 of 14 ml/min/kg. A BNP concentration
316 pg/ml constitutes a 6.8-fold higher risk for a reduced
exercise capacity with a peak VO2 14 ml/min/kg. How-
ever, peak VO2 is a continuous, rather than a discrete
variable, and the evidence of an optimal cutoff point seems
questionable (22). Our data underline the importance of
peak VO2. The best correlation with BNP as a marker of
neuroendocrine activation in chronic HF was seen for peak
VO2 and, to a comparable degree, also for VO2-AT.
Maximum exercise level, EqCO2 and also LVEF correlated
less with BNP. Because there is a good correlation of BNP
and exercise capacity, the determination of resting BNP
might be a simple and cost-saving alternative in the future
to select patients for heart transplantation compared with
the more expensive and time-consuming exercise testing,
which is not without risk in patients with chronic HF.
Moreover, the prognostic power of plasma BNP assessing
the mortality in patients with chronic HF has already been
shown by Tsutamoto et al. (26).
Study limitations. There are several limitations of our
study. First, we did not perform invasive hemodynamic tests
to evaluate the relation between hemodynamics and BNP.
Previous studies have already shown that there is a close
correlation between BNP levels and left ventricular end-
diastolic pressure. Secondly, we did not study the influence
of medications on BNP. All patients were treated according
to chronic HF guidelines. Previous studies demonstrated
that BNP levels are reduced after treatment with beta-
blockers (27), whereas they are increased after treatment
with angiotensin-converting enzyme inhibitors (28) or dig-
italis (29). Finally, patients with renal failure were excluded
from the study because of potentially marked elevation of
plasma BNP (30,31). Thus, it remains unknown whether
plasma BNP levels can also be used to predict functional
capacity in these patients.
Conclusions. Brain natriuretic peptide testing may be an
effective way to improve monitoring and therapy of patients
with chronic HF, including in-hospital and outpatient
management. Brain natriuretic peptide is clearly associated
with exercise capacity and LVEF in chronic HF. Brain
natriuretic peptide is able to differentiate between patients
with chronic HF with moderately and severely impaired
exercise capacity. Further studies are needed to compare the
prognostic value, outcome, and cost-effectiveness of BNP-
guided versus exercise-testing-guided therapy in chronic
HF.
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